When the denominator stays small
The disease came back in 9.4% of the 202 patients who had surgery; the figure was 6% at stage 2 and 19.5% at stage 3. Median follow-up reached 62.6 months, so a short observation period does not on its own explain how few events there were.[1]
Patients who received adjuvant chemotherapy did not have better recurrence-free survival: the multivariable hazard ratio was 0.98, with a 95% confidence interval from 0.43 to 2.28. In the same series, five-year overall survival fell to 77.2% among patients who relapsed and stayed at 95.7% among those who did not.[1]
The width of the interval
19 relapse events leave no power to separate a moderate chemotherapy effect. The lower end of the confidence interval is consistent with almost halving the risk of relapse and the upper end with almost doubling it, and the distance between those ends says how coarse the measurement itself is.[1]
Because the chemotherapy decision follows the clinician's risk assessment, the treated group may have been higher risk from the start. Such a selection could wash out a real benefit, and a retrospective cohort cannot settle that possibility on its own.[1]
The decision in front of the patient
The weight of relapse sits in the numbers: five-year overall survival is 95.7% among patients without relapse and drops to 77.2% among those with it. Preventing relapse therefore remains a clinically important target, and the chemotherapy question is not an idle argument.[1]
What the evidence says is this: with these data, a benefit from adjuvant chemotherapy could not be shown. The conclusion that there is no benefit is a separate claim, and this series is not strong enough to carry it. The 19.5% relapse rate at stage 3 leaves open the question of who beneath the average might still benefit, and that uncertainty is exactly what a patient should hear.[1]